• Home
  • Publications
  • Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data

Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data

J. Photochem. Photobiol. B 2022, 233, 112479

DOI: 10.1016/j.jphotobiol.2022.112479

Komarov I.; Tolstanova G.; Kuznietsova H.; Dziubenko N.; Yanchuk P.; Shtanova L.; Veselsky S.; Garmanchuk L.; Khranovska N.; Gorbach O.; Dovbynchuk T.; Borysko P.; Babii O.; Schober T.; Ulrich A.; Afonin S.

An in vivo study of a photoswitchable cytotoxic peptide LMB040 has been undertaken on a chemically induced hepatocellular carcinoma model in immunocompetent rats. We analysed the pharmacokinetic profile of the less toxic photoform (“ring-closed” dithienylethene) of the compound in tumors, plasma, and healthy liver. Accordingly, the peptide can reach a tumor concentration sufficiently high to exert a cytotoxic effect upon photoconversion into the more active (“ring-open”) photoform. Tissue morphology, histology, redox state of the liver, and hepatic biochemical parameters in blood serum were analysed upon treatment with (i) the less active photoform, (ii) the in vivo light-activated alternative photoform, and (iii) compared with a reference chemotherapeutic 5-fluorouracil. We found that application of the less toxic form followed by a delayed in vivo photoconversion into the more toxic ring-open form of LMB040 led to a higher overall survival of the animals, and signs of enhanced immune response were observed compared to the untreated animals.

Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data

FOLLOW US